Medicine Recommendations

For the treatment of refractory / resistant depression.

Liothyronine monotherapy for the management of chronic hypothyroidism – primary and secondary care

Add-on treatment for refractory hypothyroidism – existing patients.

Liothyronine therapy commenced in the private sector

Type 2 diabetes mellitus (NICE NG28)

NICE NG28 - Type 2 diabetes in adults: management

NICE TA664 - For managing overweight and obesity

ADHD in adults

ADHD in children and young adults

Mania, bipolar disorder and recurrent depression

Type 2 diabetes mellitus

Suitable for initiation in primary care in line with restrictions (see background paragraph)

Depressive illness

Insomnia (short term use)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Breathlessness

Breathlessness in the last days of life

Short term use in anxiety and insomnia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Short term use in anxiety and insomnia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Insomnia (short term use)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Various indications

The colour classification is dependant on the indication. See LMWH Summary Prescribing Guide for more details. 

Schizophrenia or bipolar disorder (NICE TA286 - terminated appraisal)

NICE TA286 - Loxapine Inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal)

Treatment of schizophrenia in adults aged 18 and over

For treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)